AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emyria Ltd

0.030

-0.001-3.23%

Volume:62.22K

Turnover:1.82K

Market Cap:14.74M

PE:-7.41

High:0.031

Open:0.031

Low:0.029

Close:0.031

Loading ...

Overview Company News Filings

Emyria opens second Empax centre in Perth to meet mental health demand

The Market Herald

Favourable Signals For Emyria: Numerous Insiders Acquired Stock

Simply Wall St.

BRIEF-Emyria Says Loss For Half-Year Attributable A$968,997

Emyria Ltd - Loss for Half-Year Attributable a$968,997

THOMSON REUTERS

Emyria Reports Reduced Symptoms in Post-Traumatic Stress Disorder Study; Shares Up 3%

MT Newswires Live

BUZZ-Australia's Emyria climbs to nearly two-month high on positive drug trial results

Emyria's Non-Executive Chair Transitions to Executive Chairman

MT Newswires Live

BRIEF-Emyria Says Greg Hutchinson Will Assume Role Of Executive Chair

Emyria Ltd - Greg Hutchinson Will Assume Role of Executive Chairman

THOMSON REUTERS

Leadership reshuffle at Emyria as mental-health biotech readies for year of growth

Business News Australia

Insiders Give Up AU$265k As Emyria Stock Drops To AU$0.03

Simply Wall St.

Emyria to plug $2.5M into depression treatment program at Empax Centre

The Market Herald

Emyria Ltd-Emyria Secures $2.525M in Strongly Supported Placement

THOMSON REUTERS

BRIEF-Emyria Says Trading Halt Requested

Emyria Ltd-Investor Update - November 2024

THOMSON REUTERS

Emyria and UWA seek commercialisation of compounds to treat PTSD and Parkinson’s

The Market Herald

BRIEF-Emyria Secures Ethics Endorsement For Psilocybin-Assisted Therapy Program

Emyria Ltd - Emyria Secures Ethics Endorsement for Psilocybin-Assisted Therapy Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EMD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMD.AU\",,,,,undefined,":{"symbol":"EMD.AU","market":"AU","secType":"STK","nameCN":"Emyria Ltd","latestPrice":0.03,"timestamp":1744870320000,"preClose":0.031,"halted":0,"volume":62216,"delay":0,"nameEN":"Emyria Ltd","floatShares":250256279,"shares":491244158,"eps":-0.004046,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"04-17 16:12:00 AEST","open":0.031,"high":0.031,"low":0.029,"amount":1820,"amplitude":0.064516,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.004046,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.031,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.4994444906656977,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMD.AU\",,,,,undefined,":{"symbol":"EMD.AU","floatShares":250256279,"roa":"-10.14%","roe":"-74.80%","lyrEps":-0.031912,"volumeRatio":0.4994444906656977,"shares":491244158,"dividePrice":0,"high":0.031,"amplitude":0.064516,"preClose":0.031,"low":0.029,"week52Low":0.021,"pbRate":"4.32","psRate":"8.32","week52High":0.064,"institutionHeld":0,"latestPrice":0.03,"eps":-0.004046,"divideRate":0,"volume":62216,"delay":0,"ttmEps":-0.004046,"open":0.031,"prevYearClose":0.034,"prevWeekClose":0.03,"prevMonthClose":0.031,"prevQuarterClose":0.031,"fiveDayClose":0.029,"twentyDayClose":0.032,"sixtyDayClose":0.034},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527949352","title":"Emyria opens second Empax centre in Perth to meet mental health demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2527949352","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527949352?lang=en_us&edition=fundamental","pubTime":"2025-04-14 08:35","pubTimestamp":1744590900,"startTime":"0","endTime":"0","summary":"A year after opening its first ‘Empax’ centre in Leederville, Western Australia, Emyria Ltd  has opened a second – this time within the eminent mental health hospital, the Perth Clinic.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.In this way, it aims to expand its provision of programs supporting patients with both PTSD and treatment-resistant depression – including through psychedelic-assisted therapies – by 50%.The first 2 fully funded patients will be commencing treatment on 14 April, with this underscoring both the activation of the Perth Clinic site and the company’s intention to roll out a broader strategy to meet clinical demand – with the latter also reflecting structural changes in mental health care funding.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-opens-second-empax-centre-in-perth-to-meet-mental-health-demand-2025-04-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7502","EMD.AU","BK7096","BK7113"],"gpt_icon":0},{"id":"2517087989","title":"Favourable Signals For Emyria: Numerous Insiders Acquired Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2517087989","media":"Simply Wall St.","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517087989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:09","pubTimestamp":1741122579,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Emyria Limited , that sends out a positive message to the company's shareholders.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.In the last twelve months, the biggest single sale by an insider was when the insider, Sufian Ahmad, sold AU$672k worth of shares at a price of AU$0.04 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of AU$0.032. So it may not shed much light on insider confidence at current levels. The only individual insider seller over the last year was Sufian Ahmad.For the purposes of this article, insiders are those individ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/favourable-signals-emyria-numerous-insiders-210939461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7502","EMD.AU","BK7113","BK7096"],"gpt_icon":0},{"id":"2514757815","title":"BRIEF-Emyria Says Loss For Half-Year Attributable A$968,997","url":"https://stock-news.laohu8.com/highlight/detail?id=2514757815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514757815?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:37","pubTimestamp":1740620247,"startTime":"0","endTime":"0","summary":"BRIEF-Emyria Says Loss For Half-Year Attributable A$968,997Feb 27 (Reuters) - Emyria Ltd EMD.AX:EMYRIA LTD - LOSS FOR HALF-YEAR ATTRIBUTABLE A$968,997Further company coverage: EMD.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7502","BK7096","EMD.AU","BK7113"],"gpt_icon":0},{"id":"2514896645","title":"Emyria Ltd - Loss for Half-Year Attributable a$968,997","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896645?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:22","pubTimestamp":1740608555,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","EMD.AU","BK7113","BK7096"],"gpt_icon":0},{"id":"2508506100","title":"Emyria Reports Reduced Symptoms in Post-Traumatic Stress Disorder Study; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508506100","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508506100?lang=en_us&edition=fundamental","pubTime":"2025-02-04 12:45","pubTimestamp":1738644316,"startTime":"0","endTime":"0","summary":"Emyria (ASX:EMD) reported a reduction in the symptoms of patients diagnosed with post-traumatic stress disorder (PTSD) who underwent its therapy program, according to a Tuesday filing with the Austral","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4212","BK7502","BK7096","BK7113","POST","EMD.AU"],"gpt_icon":0},{"id":"2508109150","title":"BUZZ-Australia's Emyria climbs to nearly two-month high on positive drug trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2508109150","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508109150?lang=en_us&edition=fundamental","pubTime":"2025-02-04 10:47","pubTimestamp":1738637247,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Emyria climbs to nearly two-month high on positive drug trial results** Shares of Emyria EMD.AX rise 2.9% to A$0.036, their highest levels since Dec 11** The early-stage drug developer announces positive interim analysis results of its MDMA-assisted therapy programme for Post Traumatic Stress Disorder ** Co says therapy programme clinically reduces PTSD symptoms in first eight patients** Stock rose as much as 14.3% to A$0.040 earlier in the day, marking its biggest intraday gain since Jan 22** About 1.3 mln shares change hands, 6.9 times the 30-day average of 189,038** Stock has risen 5.9% YTD, including current session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nL4N3OV05K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7113","BK7502","BK7096","EMD.AU"],"gpt_icon":0},{"id":"2505913059","title":"Emyria's Non-Executive Chair Transitions to Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2505913059","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505913059?lang=en_us&edition=fundamental","pubTime":"2025-01-23 14:43","pubTimestamp":1737614636,"startTime":"0","endTime":"0","summary":"Emyria  said Non-Executive Chair Greg Hutchinson will assume the role of Executive Chairman, according to a Wednesday filing with the Australian bourse.Chief Executive Officer Michael Winlo will transition into the new role of Chief Scientific Officer, reporting to the executive chairman, the filing said.Shares of the company rose 9% at market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7113","XJO.AU","BK7096","BK7502","XKO.AU","EMD.AU"],"gpt_icon":0},{"id":"2505607753","title":"BRIEF-Emyria Says Greg Hutchinson Will Assume Role Of Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2505607753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505607753?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:33","pubTimestamp":1737509594,"startTime":"0","endTime":"0","summary":"Jan 22 (Reuters) - Emyria Ltd   :   * GREG HUTCHINSON WILL ASSUME ROLE OF EXECUTIVE CHAIRMAN Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7502","BK7113","EMD.AU"],"gpt_icon":0},{"id":"2505387847","title":"Emyria Ltd - Greg Hutchinson Will Assume Role of Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2505387847","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505387847?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:21","pubTimestamp":1737498079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMD.AU","BK7502","BK7096","BK7113"],"gpt_icon":0},{"id":"2505059594","title":"Leadership reshuffle at Emyria as mental-health biotech readies for year of growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2505059594","media":"Business News Australia","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505059594?lang=en_us&edition=fundamental","pubTime":"2025-01-22 00:00","pubTimestamp":1737475200,"startTime":"0","endTime":"0","summary":"Perth-based Emyria (ASX: EMD), an ASX-listed biotech that specialis...","market":null,"thumbnail":"https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67903654bded9.jpg?v=2&m=0c9ee978432a9b17d97e1641d54dfe30&lqip(10)","type":0,"news_type":0,"thumbnails":["https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/67903654bded9.jpg?v=2&m=0c9ee978432a9b17d97e1641d54dfe30&lqip(10)"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessnewsaustralia.com/articles/leadership-reshuffle-at-emyria-as-mental-health-biotech-readies-for-year-of-growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"businessau_stock","symbols":["EMD.AU","BK7502","BK7096","BK7113","KAT.AU"],"gpt_icon":0},{"id":"2505646622","title":"Insiders Give Up AU$265k As Emyria Stock Drops To AU$0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2505646622","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505646622?lang=en_us&edition=fundamental","pubTime":"2025-01-21 04:15","pubTimestamp":1737404104,"startTime":"0","endTime":"0","summary":"Insiders who acquired AU$709.7k worth of Emyria Limited's ( ASX:EMD ) stock at an average price of AU$0.048 in the past...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-emd/emyria-shares/news/insiders-give-up-au265k-as-emyria-stock-drops-to-au003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMD","EMD.AU","BK7113","BK7096","BK7502"],"gpt_icon":0},{"id":"2486403864","title":"Emyria to plug $2.5M into depression treatment program at Empax Centre","url":"https://stock-news.laohu8.com/highlight/detail?id=2486403864","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486403864?lang=en_us&edition=fundamental","pubTime":"2024-11-27 10:21","pubTimestamp":1732674060,"startTime":"0","endTime":"0","summary":"Emyria Ltd  is raising more than two and a half million dollars to facilitate expansion of the mental health treatment services offered at its ‘Empax Centre’ in Perth with a placement supported by sophisticated and professional investors.The company has received firm commitments from the latter for the placement, with shares priced at 3.5 cents for a total raise of $2.525 million.Within this, chairman Greg Hutchinson contributed a cornerstone subscription of $1 million.Among the services to be expanded at the Empax Centre – which opened in April – is a treatment-resistant depression program for which Emyria has recently received approval.Chairman Greg Hutchinson said the development of such a program was timely.“As the only ASX-listed company delivering direct care in this field, our mission is clear: to expand access to our innovative treatments, improving the lives of more Australians.”The material provided in this article is for information only and should not be treated as investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-to-plug-2-5m-into-depression-treatment-program-at-empax-centre-2024-11-27/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7502","EMD.AU","BK7113","BK7096"],"gpt_icon":0},{"id":"2486856896","title":"Emyria Ltd-Emyria Secures $2.525M in Strongly Supported Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856896?lang=en_us&edition=fundamental","pubTime":"2024-11-27 07:08","pubTimestamp":1732662534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUEC3V0H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7502","EMD.AU","BK7113"],"gpt_icon":0},{"id":"2486743174","title":"BRIEF-Emyria Says Trading Halt Requested","url":"https://stock-news.laohu8.com/highlight/detail?id=2486743174","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486743174?lang=en_us&edition=fundamental","pubTime":"2024-11-25 08:25","pubTimestamp":1732494322,"startTime":"0","endTime":"0","summary":"Nov 25 (Reuters) - Emyria Ltd   :   * TRADING HALT REQUESTED PENDING CAPITAL RAISING ANNOUNCEMENTFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMD.AU","BK7113","BK7096","BK7502"],"gpt_icon":0},{"id":"2486717611","title":"Emyria Ltd-Investor Update - November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486717611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486717611?lang=en_us&edition=fundamental","pubTime":"2024-11-25 06:59","pubTimestamp":1732489153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241124:nTUE8GXFS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BK7096","EMD.AU","BK7113"],"gpt_icon":0},{"id":"2479794256","title":"Emyria and UWA seek commercialisation of compounds to treat PTSD and Parkinson’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2479794256","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479794256?lang=en_us&edition=fundamental","pubTime":"2024-10-31 08:18","pubTimestamp":1730333880,"startTime":"0","endTime":"0","summary":"Emyria Ltd  and the University of Western Australia  have signed off on a licence agreement to secure global rights to a library of patented serotonin-releasing agents inspired by MDMA targeting various mental health and neurological conditions.The company and university have been involved in a research partnership since 2021 which helped to discover these compounds, which they are now seeking to commercialise. Among the achievements of their collective research has been the creation of compounds which induce serotonin release without releasing dopamine or noradrenaline.Studies done so far point to the possibility of reducing the half-life of these novel compounds, which allows for shorter therapeutic windows suited to psychotherapy.With the licence agreement finalised, two lead compounds, MX-100 and MX-200 – which target PTSD and Parkinson’s – are being prepared for advanced screening.Both are to be fast-tracked through preclinical testing – with this supported by a $499,411 WA govern","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-and-uwa-seek-commercialisation-of-compounds-to-treat-ptsd-and-parkinsons-2024-10-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["EMD.AU","BK7502","BK7096","BK7113"],"gpt_icon":0},{"id":"2478119119","title":"BRIEF-Emyria Secures Ethics Endorsement For Psilocybin-Assisted Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2478119119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478119119?lang=en_us&edition=fundamental","pubTime":"2024-10-28 09:10","pubTimestamp":1730077836,"startTime":"0","endTime":"0","summary":"Oct 28 (Reuters) - Emyria Ltd   :   * EMYRIA SECURES ETHICS ENDORSEMENT FOR PSILOCYBIN-ASSISTED THERAPY PROGRAM Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7113","EMD.AU","BK7096","BK7502"],"gpt_icon":0},{"id":"2478619713","title":"Emyria Ltd - Emyria Secures Ethics Endorsement for Psilocybin-Assisted Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2478619713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478619713?lang=en_us&edition=fundamental","pubTime":"2024-10-28 07:01","pubTimestamp":1730070061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241027:nFWN3M300E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMD.AU","BK7502","BK7096","BK7113"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMD.AU\",market:\"AU\",,,undefined,":[]}}